Business Wire

Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets *1 Initiative Based on Science-based Net-zero Targets

Share

Kirin Holdings Company, Limited (Kirin Holdings) has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi*2 in July 2022. The Kirin Group’s long-term GHG reduction target , "realizing net-zero*3 GHG*4 emission from the entire value chain by 2050" set forth in the Kirin Group Environmental Vision 2050 was certified as a scientifically based goal consistent with the level of GHG emission reductions required by the Paris Agreement*5 .

Kirin Holdings, with the aim of becoming " A global leader in CSV*6”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision 2050 and have formulated a roadmap for achieving the goal, which went into operation in January 2022.

A sense of crisis was shared around the world on the issue of climate change in the wake of the 2015 Paris Agreement, the 2018 IPCC 1.5°C Special Report*7 reported that global warming from pre-industrial times must be limited to 1.5°C and GHG emissions must be reduced to net zero by around 2050. In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets. However, since there is no common standard for corporate net-zero targets, the scope of GHG emissions to be covered, the means to achieve net-zero, and the level of GHG reductions differ, and thus a divergence from the target needed to limit global warming to 1.5°C has been pointed out.

In response to this flurry of net-zero targets, the SBT Initiative developed the "Net Zero Standard" in October 2021. This standard stipulates that in order to limit global warming to 1.5°C, companies must reduce GHG emissions by at least 90% across their value chains by 2050, and the net-zero can be achieved by removing the remaining 10% of GHG emissions from the atmosphere.

In order to achieve The Kirin Group’s long-term goal, Kirin Holdings has set a mid-term target for 2030 (to reduce the total of Scope 1 and Scope 2 for the entire group by 50% and Scope 3 by 30% by 2030 compared to 2019), and is promoting GHG reduction in our value chain with the technological capabilities we have cultivated over the years. For Scope 1 and Scope 2, we have installed heat pumps at six Kirin Brewery breweries in Japan, utilizing our plant engineering capabilities to reduce GHG emissions by approximately 3,800 tons per year. In terms of Scope 3, we are gradually expanding the use of "R100 PET bottles" made of 100% recycled PET resin, and are rolling them out for some of ourKirin Nama-cha brands.

With the goal of achieving net zero emissions by 2050, Kirin Holdings will continue to work toward the realization of the Kirin Group Environmental Vision 2050, which aims to strengthen the resilience of society and the company, and to lead the way toward the creation of a decarbonized society.

1:

Science Based Targets: Greenhouse gas reduction targets based on scientific evidence.

2:

An international initiative jointly established in 2015 by CDP, the UN Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).

3:

A state in which anthropogenic GHG emissions and removals are balanced and GHG emissions to the atmosphere are net zero.

4:

Green House Gas

5:

International framework for global warming countermeasures in which all countries and regions participate

6:

Creating Shared Value. Combined added value for consumers as well as for society at large.

7:

This report published by the Intergovernmental Panel on Climate Change (IPCC) describes the significant difference between 2°C and 1.5°C in terms of the impact of future temperature increases and the emission pathways to limit the increase to 1.5°C.

[Reference]
・Kirin Group Environmental Vision 2050
https://www.kirinholdings.com/en/impact/env/mission/

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact
Corporate Communications Department, Kirin Holdings Company, Limited
Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo
Tel: +81-3-6837-7028 Fax: +81-3-3319-6216
email: kirin-cc@kirin.co.jp
https://www.kirinholdings.com/en/

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dentalis Animal Health appoints Advisory Board4.2.2023 15:09:00 CET | Press release

Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pharmaceutical Industry veteran with broad international business experience. A graduate of Harvard Business School and Cornell University, Michael was hired by Ciba-Geigy to begin his post graduate career in Switzerland. Eventually ending up in the Novartis Animal Health US Division (following the Ciba-Sandoz merger) he rose to CFO and VP of North America. In 2009 Kelly joined Piedmont Animal Health (PAH), a drug development company, and served various roles including CFO, COO and President. During his tenure at PAH the organization received more FDA Companion Animal Drug approvals than any other Company in the Industry. Dr Stephanie Livermore Dr. Stephanie Livermore has been practicing companion animal medicine and surgery since her graduation from the University of Guelph in 2008. Dr. Livermore

Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways4.2.2023 09:00:00 CET | Press release

Autel, a leading provider of automotive electronics and diagnostic equipment and tools, exhibited for the first time at eCarExpo, the largest electric vehicles fair in the Nordic countries, on February 3-5, 2023, in Friends Arena, Stockholm. Autel brought its portfolio of products featuring the recently launched electric vehicle charger the MaxiCharger DC Compact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005001/en/ Autel signs partnership agreement with leading charging operator Eways (Photo: Business Wire) As Autel's newly launched DC charger for EVs, the MaxiCharger DC Compact is not only sleek and compact with a 21.5-inch LCD touchscreen, but also powerful enough to provide up to 47kW of power for the European version. Either placed on a pedestal, or set on wheels for ultimate portability, the MaxiCharger DC Compact is perfect for charging operators wanting to provide their customers with a quick charge option

U.S. FDA Approves Takeda’s TAKHZYRO ® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older4.2.2023 00:48:00 CET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age required dosing every three to four days,and children with HAE 2 to <6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group.1-5 The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to <6 years of age and every two weeks in patients 6 to <12 years of age.1 HAE attacks can involve serious and debilitating swelling in the abdomen, face, feet, genitals, hands and throat.5,7 Potentially fatal upper airway angioedema has been reported i

SLB Completes Acquisition of Gyrodata Incorporated3.2.2023 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced it has completed the acquisition of Gyrodata Incorporated, a global company specializing in gyroscopic wellbore positioning and survey technology. The transaction will incorporate Gyrodata’s wellbore placement and surveying technologies within SLB’s Well Construction business, bringing customers innovative drilling solutions. This combination will improve wellbore quality and reduce drilling risk to unlock even the most remote and complex reservoirs. Integrating three-axis solid state gyro measurements with the latest SLB technological innovations will help ensure tighter trajectory control, reduce data acquisition time and improve the decision-making process—resulting in greater overall drilling efficiency. “I’m excited for this historic moment that will bring innovative solutions to the SLB Well Construction division and our industry,” said Jesus Lamas, president, Well Construction, SLB. “The technology-driven acquisition of Gyrodata is aligned with SL

Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 16:17:00 CET | Press release

The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom